PARP1 and neoplasm: The observed stronger cytotoxicity of the combination of an HDACi, PARPi, and alkylating agent may be attributed to the fact that one of the mechanisms underlying tumor resistance to PARP inhibitors is the activation of the HR DNA repair pathway.